• Something wrong with this record ?

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma

L. Besse, L. Sedlarikova, F. Kryukov, J. Nekvindova, L. Radova, O. Slaby, P. Kuglik, M. Almasi, M. Penka, M. Krejci, Z. Adam, L. Pour, S. Sevcikova, R. Hajek,

. 2015 ; 10 (9) : e0137294. [pub] 20150921

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020276

Grant support
NT14575 MZ0 CEP Register

Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extramedullary disease from myeloma patients without such manifestation and from healthy donors. MicroRNA-130a was identified by TaqMan Low Density Arrays and verified by quantitative PCR on 144 serum samples (59 multiple myeloma, 55 myeloma with extramedullary disease, 30 healthy donors) in test and validation cohorts as being down-regulated in myeloma patients with extramedullary disease. Circulating microRNA-130a distinguished myeloma patients with extramedullary disease from healthy donors with specificity of 90.0% and sensitivity of 77.1%, patients with extramedullary disease from newly diagnosed multiple myeloma patients with specificity of 77.1% and sensitivity of 34.3% in the test cohort and with specificity of 91.7% and sensitivity of 30.0% in the validation cohort of patients. Circulating microRNA-130a in patients with extramedullary myeloma was associated with bone marrow plasma cells infiltration. Further, microRNA-130a was decreased in bone marrow plasma cells obtained from patients with extramedullary myeloma in comparison to bone marrow plasma cells of myeloma patients without such manifestation, but it was increased in tumor site plasma cells of patients with extramedullary disease compared to bone marrow plasma cells of such patients (p<0.0001). Together, our data suggest connection between lower level of microRNA-130a and extramedullary disease and prompt further work to evaluate this miRNA as a marker of extramedullary disease in multiple myeloma.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020276
003      
CZ-PrNML
005      
20200219094011.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0137294 $2 doi
024    7_
$a 10.1371/journal.pone.0137294 $2 doi
035    __
$a (PubMed)26389804
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bešše, Lenka, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $d 1985- $7 mub2014851432
245    10
$a Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma / $c L. Besse, L. Sedlarikova, F. Kryukov, J. Nekvindova, L. Radova, O. Slaby, P. Kuglik, M. Almasi, M. Penka, M. Krejci, Z. Adam, L. Pour, S. Sevcikova, R. Hajek,
520    9_
$a Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extramedullary disease from myeloma patients without such manifestation and from healthy donors. MicroRNA-130a was identified by TaqMan Low Density Arrays and verified by quantitative PCR on 144 serum samples (59 multiple myeloma, 55 myeloma with extramedullary disease, 30 healthy donors) in test and validation cohorts as being down-regulated in myeloma patients with extramedullary disease. Circulating microRNA-130a distinguished myeloma patients with extramedullary disease from healthy donors with specificity of 90.0% and sensitivity of 77.1%, patients with extramedullary disease from newly diagnosed multiple myeloma patients with specificity of 77.1% and sensitivity of 34.3% in the test cohort and with specificity of 91.7% and sensitivity of 30.0% in the validation cohort of patients. Circulating microRNA-130a in patients with extramedullary myeloma was associated with bone marrow plasma cells infiltration. Further, microRNA-130a was decreased in bone marrow plasma cells obtained from patients with extramedullary myeloma in comparison to bone marrow plasma cells of myeloma patients without such manifestation, but it was increased in tumor site plasma cells of patients with extramedullary disease compared to bone marrow plasma cells of such patients (p<0.0001). Together, our data suggest connection between lower level of microRNA-130a and extramedullary disease and prompt further work to evaluate this miRNA as a marker of extramedullary disease in multiple myeloma.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x analýza $x krev $x genetika $7 D014408
650    _2
$a kostní dřeň $x patologie $7 D001853
650    _2
$a ženské pohlaví $7 D005260
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x analýza $x krev $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x krev $x diagnóza $x genetika $x patologie $7 D009101
650    _2
$a plazmatické buňky $x patologie $7 D010950
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sedlaříková, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $7 xx0214571
700    1_
$a Kryukov, Fedor $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Hematooncology, Faculty of Medicine University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic. $7 xx0128646
700    1_
$a Nekvindová, Jana $u Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. $7 xx0207729
700    1_
$a Radova, Lenka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Slabý, Ondřej, $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $d 1981- $7 js20030220015
700    1_
$a Kuglík, Petr, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $d 1957- $7 ola2003204793
700    1_
$a Almasi, Martina $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $7 gn_A_00004597
700    1_
$a Penka, Miroslav, $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $d 1952- $7 nlk19990073680
700    1_
$a Krejčí, Marta, $u Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic. $d 1969- $7 jx20080512017
700    1_
$a Adam, Zdeněk $u Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic. $7 jn19981000018
700    1_
$a Pour, Luděk $u Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic. $7 xx0102556
700    1_
$a Ševčíková, Sabina, $d 1972- $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $7 mub2015859787
700    1_
$a Hájek, Roman, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic; Department of Hematooncology, Faculty of Medicine University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic. $d 1964- $7 nlk20000083645
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 9 (2015), s. e0137294
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26389804 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20200219094414 $b ABA008
999    __
$a ok $b bmc $g 1154946 $s 944804
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 9 $d e0137294 $e 20150921 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT14575 $p MZ0
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options